Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01176591 · ClinicalTrials.gov registry record · Phase 2
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01176591: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01176591 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01176591, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The proposed research will focus on investigating the determinants and consequences of CAD via measurement of physiological, behavioral and subjective effects of physiologic and psychologic stress cues in CAD volunteers in the laboratory, and through examination of the effects of the effects of Aprepitant, an NK1 antagonist, on the above effects. This study will examine the effects of the above stress cues on cocaine and alcohol craving under acute Aprepitant dosing, and under placebo conditions. The study is a within-subjects crossover design using 24 subjects.
Interventions
- DRUG Placebo session 1, Aprepitant session 2
- DRUG Placebo session 1, Placebo session 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01176591
The ClinicalTrials.gov registry entry for NCT01176591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo session 1, Aprepitant session 2 is the first listed.
NCT01176591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01176591 about?
NCT01176591 is a clinical study titled "HBPL Study of the Impact of the NK1 Antagonist Aprepitant". The proposed research will focus on investigating the determinants and consequences of CAD via measurement of physiological, behavioral and subjective effects of physiologic and psychologic stress cues in CAD volunteers in the laboratory, and through examination of the effects of the effects of Apre...
What is the current status of trial NCT01176591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2010-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01176591?
The interventions under investigation include: Placebo session 1, Aprepitant session 2 (DRUG), Placebo session 1, Placebo session 2 (DRUG).
Who is sponsoring clinical trial NCT01176591?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.